The malaria diagnostics market size is projected to grow from US$ 782.57 million in 2022 to US$ 1,200.24 million by 2030, registering a compound annual growth rate (CAGR) of 5.5% during 2022–2030 . This steady expansion reflects the persistent global challenge of malaria, particularly in sub-Saharan Africa and Southeast Asia, where the disease continues to affect millions annually despite elimination efforts. The market's resilience stems from ongoing public health initiatives, technological innovations in testing methodologies, and increasing investments from international organizations like the World Health Organization (WHO) and the Global Fund to Fight AIDS, Tuberculosis and Malaria.
Market Dynamics and Growth Drivers
Several interconnected factors are propelling the malaria diagnostics market forward. Primarily, the high burden of malaria in endemic regions necessitates robust diagnostic infrastructure. According to WHO estimates, there were over 249 million malaria cases worldwide in 2022, underscoring the demand for accessible, accurate testing solutions . Governments and NGOs are scaling up screening programs, particularly in remote and resource-limited settings, which favors point-of-care technologies.
Technological evolution plays a pivotal role. Traditional microscopy, while cost-effective, is labor-intensive and requires skilled personnel. Rapid diagnostic tests (RDTs) have revolutionized field diagnostics with their simplicity and speed, detecting malaria antigens in under 15 minutes. Molecular diagnostic tests, leveraging PCR and nucleic acid amplification, offer superior sensitivity for low-parasite-density infections and are increasingly vital for surveillance and drug resistance monitoring .
End-user preferences are shifting toward integrated solutions. Hospitals and clinics, handling the bulk of confirmed cases, prioritize high-throughput systems for emergency triage. Diagnostic centers, meanwhile, focus on large-scale testing for epidemiological studies and outbreak response. The post-pandemic emphasis on resilient supply chains has also boosted local manufacturing of RDTs, reducing dependency on imports .
Challenges persist, including test stockouts, counterfeit products, and varying regulatory standards across regions. However, opportunities abound in digital integration—such as AI-enhanced microscopy readers and connected RDTs that enable real-time data reporting to national surveillance systems.
Detailed Market Segmentation
By Technology
Microscopy: Remains the gold standard for species identification and parasite quantification, dominant in well-equipped laboratories despite training barriers .
Rapid Diagnostic Tests (RDTs): Account for over 60% market share due to portability and ease-of-use; histidine-rich protein 2 (HRP2) and lactate dehydrogenase (pLDH) antigens are common targets .
Molecular Diagnostic Tests: Growing fastest at ~7% CAGR, driven by needs for mutation detection in artemisinin-resistant strains; loop-mediated isothermal amplification (LAMP) offers field viability .
By End User
Hospitals and Clinics: Largest segment (~70%), serving acute cases with integrated lab services .
Diagnostic Centers: Expanding for centralized testing, quality control, and research applications .
Geographically, Asia-Pacific leads growth due to population density and government programs like India's National Vector Borne Disease Control Programme, while Africa dominates volume.
Competitive Landscape and Key Players
The market features a mix of global giants and specialized players innovating in sensitivity, multiplexing, and affordability. Leading companies include:
Access Bio., Inc.: Renowned for CARESTART RDTs, expanding in Africa via partnerships .
Abbott Laboratories: ID NOW platform combines molecular speed with portability .
Premier Medical Corporation Pvt. Ltd.: India-based, focusing on cost-effective RDTs for domestic and export markets .
Sysmex Partec GmbH: CyFlow miniPOCT for fluorescence-based detection .
bioMérieux: BioFire systems for syndromic panels including malaria .
Beckman Coulter, Inc.: Automated hematology analyzers with malaria modules .
Siemens Healthineers: Atellica platforms for high-volume screening .
Leica Microsystems GmbH: Advanced microscopy solutions .
Nikon Corporation: High-resolution imaging for research .
These firms pursue strategies like WHO prequalification, local production, and R&D collaborations. Mergers, such as potential diagnostics consolidations, could reshape dynamics.
Emerging Trends and Future Outlook
Digital health integration is transformative—smartphone-linked RDT readers and blockchain for result verification enhance accuracy and traceability. Multiplex assays detecting malaria alongside dengue or COVID-19 address co-infection challenges. Sustainability trends favor eco-friendly test kits, while AI algorithms improve microscopy automation, potentially bridging the skilled microscopist gap.
Related Reports:
Veterinary Diagnostics Products Market Growth Analysis, Share and Regional Trends to 2031
Companion Animal Diagnostics Market Size and Growth 2031
Infectious Disease In vitro Diagnostics Market Size and Growth 2031
About Us:
The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials.
Contact Us:
If you have any queries about this report or if you would like further information, please get in touch with us:
Contact Person: Ankit Mathur
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876
Also Available in :Korean German Japanese French Chinese Italian Spanish
